Another key patent on the CRISPR genome editing technology is facing a legal challenge. On Tuesday, St. Louis-based Benson Hill Biosystems, a privately held agriculture biotech company, filed a petition for post-grant review with the U.S. Patent and Trademark Office, arguing that a CRISPR patent granted to the Broad Institute of MIT and Harvard in 2017 and licensed by Editas Medicine (EDIT) is invalid.

The challenged patent (number 9,790,490) covers CRISPR systems that use not the original Cas9 enzyme but a family of enzymes that the Broad’s Feng Zhang and his colleagues discovered in 2015. Originally called Cpf1 and now known as Cas12a, this family of enzymes cleave DNA at a target site, as Cas9 does. But Cpf1 has several advantages over the original, including working at regions of the genome that are inaccessible to Cas9 and being able to cut DNA without the addition of a molecule called tracrRNA.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy